Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2001
08/30/2001WO2001062257A2 Bupropion metabolites and methods of their synthesis and use
08/30/2001WO2001062256A1 Novel galenical form for oral administration with prolonged release of molsidomine
08/30/2001WO2001062255A1 Antiviral azaindole derivatives
08/30/2001WO2001062254A1 Patches containing buprenorphine hydrochloride
08/30/2001WO2001062253A1 Compositions and methods for treatment of epilepsy
08/30/2001WO2001062252A1 Tyrosine kinase inhibitors
08/30/2001WO2001062251A1 Tyrosine kinase inhibitors
08/30/2001WO2001062250A1 Thiazolium compounds and treatments of disorders associated with protein aging
08/30/2001WO2001062249A1 Use of pramipexole for the treatment of addictive disorders
08/30/2001WO2001062248A1 Orally administrable acid stable anti-ulcer benzimidazole derivatives
08/30/2001WO2001062247A1 Topical compositions containing thiazolium compounds and methods of using same
08/30/2001WO2001062246A1 Method for treating neurodegeneration
08/30/2001WO2001062245A2 Bilirubin or biliverdin degradation fragments
08/30/2001WO2001062244A1 Agents ameliorating sickness behaviors
08/30/2001WO2001062243A1 Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
08/30/2001WO2001062241A1 Method for the prevention or reduction of vascular access dysfunction
08/30/2001WO2001062239A2 Novel compositions and uses of dictyostatin compounds
08/30/2001WO2001062238A2 Ppar gamma agonists for the treatment of liver inflammatory disorders
08/30/2001WO2001062237A2 Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
08/30/2001WO2001062236A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
08/30/2001WO2001062235A2 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
08/30/2001WO2001062234A2 Dosing regimen
08/30/2001WO2001062233A2 Adenosine receptor modulators
08/30/2001WO2001062231A1 Antibiotic composition with inhibitor
08/30/2001WO2001062229A1 Therapeutic product, use and formulation thereof
08/30/2001WO2001062228A1 Method for transdermal or intradermal delivery of molecules
08/30/2001WO2001062227A2 Anticholinergic drug formulations for treatment of chronic obstr uctive pulmonary disease
08/30/2001WO2001062222A2 Cosmetic composition, especially for use on aging and/or stressed skin
08/30/2001WO2001062213A1 Squalane containing ultra fine particles of burning residue of carbon and method for producing the same
08/30/2001WO2001062207A2 Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
08/30/2001WO2001062195A1 Antibiotic and antifungal compositions
08/30/2001WO2001062156A1 Novel indocyanine dyes
08/30/2001WO2001062102A1 Feed additives, forage and agents for animals, methods for the use thereof
08/30/2001WO2001062086A1 Nutritional intervention composition for enhancing and extending satiety
08/30/2001WO2001062082A2 Use of phenylethylamine derivatives for the anitmicrobial treatment of surfaces
08/30/2001WO2001027098A3 Method for producing cox-2 inhibitors
08/30/2001WO2001026705A3 A dual adhesive transdermal drug delivery system
08/30/2001WO2001025248A3 Design of high affinity rnase h recruiting oligonucleotide
08/30/2001WO2001024842A3 Hybrid matrices and hybrid matrix mixtures
08/30/2001WO2001014576A3 Process and intermediates for the preparation of isoxazolecaroxamides and analogues
08/30/2001WO2001013927A3 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof
08/30/2001WO2001013907A3 Pharmaceutical combination for the treatment of viral infections containing a calcium channel blocker and a quinoline
08/30/2001WO2001012606A3 Tetrahydroquinoline derivatives having retinoid-like biological activity
08/30/2001WO2001012228A3 Compositions for treating viral infections, and methods therefor
08/30/2001WO2001012199A3 Methoxyamine potentiation of temozolomide anti-cancer activity
08/30/2001WO2001012195A3 Use of morphine derivatives as medicaments for the treatment of neuropathic problems
08/30/2001WO2001010430A3 Use of estrogen compounds for prevention and treatment of ischemic damage
08/30/2001WO2001010378A3 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations
08/30/2001WO2001009325A3 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations
08/30/2001WO2001007028A3 The use of retinoid receptor antagonists in the treatment of prostate carcinoma
08/30/2001WO2001006985A3 Select amino acids as zinc-solubilizing agents in anti-viral genital formulations
08/30/2001WO2001002568A3 Human genes and gene expression products
08/30/2001WO2000071510A3 INHIBITORS OF FACTOR Xa
08/30/2001WO2000040614A9 Characterization of the soc/crac calcium channel protein family
08/30/2001WO2000040597A9 Method and composition for angiogenesis inhibition
08/30/2001US20010018598 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
08/30/2001US20010018582 Device for transdermal electrotransport delivery of fentanyl and sufentanil
08/30/2001US20010018568 Method for transdermal administration of gp iib/iiia antagonist
08/30/2001US20010018539 Antiallergens, antiinflammatory agents, antitumor agents
08/30/2001US20010018538 Silylating the corresponding carbamate compound; alkylation
08/30/2001US20010018531 Therapy for mammary or colon tumors
08/30/2001US20010018530 Alzheimer's and Parkinson disease
08/30/2001US20010018525 Modulating blood glucose concentration
08/30/2001US20010018524 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
08/30/2001US20010018522 Neuropeptide y receptor ligand
08/30/2001US20010018521 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives
08/30/2001US20010018458 Method for treating asthma utilizing optically pure ( R ) - salmeterol
08/30/2001US20010018457 Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
08/30/2001US20010018456 Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis
08/30/2001US20010018455 Medicament and therapeutical method for treating idiopathic asthenozoospermia
08/30/2001US20010018453 Reacting fatty ester with tosyl chloride or mesyl chloride
08/30/2001US20010018451 Raloxifene, tamoxifen
08/30/2001US20010018450 Amycomycin, a process for its production and its use as a pharmaceutical
08/30/2001US20010018449 Hypotensive agent, endothelial damage, arteriosclerosis, antidiabetic agents
08/30/2001US20010018448 Hemorrhagic stroke
08/30/2001US20010018447 Il-8 receptor antagonists
08/30/2001US20010018445 Thalidomide
08/30/2001US20010018444 Tropane-derivatives, their preparation and use
08/30/2001US20010018443 Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
08/30/2001US20010018440 L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections
08/30/2001US20010018439 Antidiabetic agents
08/30/2001US20010018438 Nervous system disorders; psychological disorders
08/30/2001US20010018436 Pyrimidine derivatives
08/30/2001US20010018435 Prohormones; chemical intermediate in steroid metabolism in humans
08/30/2001US20010018434 Administering an antiestrogen compound
08/30/2001US20010018433 Administering a bisphosphonate compound; prostaglandin antagonist
08/30/2001US20010018432 Skin disorders; acne, seborrhea
08/30/2001US20010018431 Method for inhibiting bone resorption
08/30/2001US20010018430 Anticancer agents, psoriasis, restenosis, atherosclerosis
08/30/2001US20010018429 Neurotransmitter
08/30/2001US20010018428 C-pyrazole A2A receptor agonists
08/30/2001US20010018418 Method of promoting angiogenesis
08/30/2001US20010018417 Of sodium lauryl sulfate, a buffering agent to provide acidic pH when the mixture is added to water, and colloidal silica; mixture added to animal feeds
08/30/2001US20010018413 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
08/30/2001US20010018198 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
08/30/2001US20010018090 Administering 1-deoxynojiriniglin or mulberry tea &/or plant powders/extracts with carbohydrate source inhibits bonding of disaccharides which are passed on to large intesine for excretion
08/30/2001US20010018076 Anti-cancer agents isolated from buckwheat rhizomes (Fagospyrum cymosum); high powered liquid chromatography; purity; tannins
08/30/2001US20010018075 Process for producing sustained-release preparation
08/30/2001US20010018074 Admixing carrier particles with a solution of (R-(Z)-alpha-(methoxyimino)-alpha-(1-azabicyclo (2.2.2)oct-e-yl) acetonitrile monohydrochloride in water for treatment of dementia
08/30/2001US20010018073 Drug delivery; steroids or hormones penetrate due to combination with destructuring agent and structuring agent in common matrix; useful in treatment of hypogonadism, infertility, or contraception